Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies

Lawrence Eichenfeld,Seth Forman,Darryl Toth,Michael Kuligowski,Amy Paller,Haobo Ren,Kim Papp,Eric Simpson,Jacek Szepietowski,May Venturanza,Leon Kircik

doi:10.25251/skin.6.supp.28

Abstract

N/A

Highlights

[NCT03745651]), ruxolitinib cream demonstrated anti-inflammatory activity with antipruritic action vs vehicle and was well tolerated in patients with AD5
● Disease control was assessed by the proportion of patients who achieved no or minimal skin lesions (IGA score of 0 or 1 [clear or almost clear skin]) and mean percentage of body surface area (BSA) affected by AD at each visit during the LTS period
● The evaluable population for disease control consisted of 166 patients who remained on ruxolitinib cream from the VC period to the LTS period (TRuE-AD1: 0.75% ruxolitinib cream, n=46; 1.5% ruxolitinib cream, n=41; TRuE-AD2: 0.75% ruxolitinib cream, n=43; 1.5% ruxolitinib cream, n=36)

Summary

Introduction

[NCT03745651]), ruxolitinib cream demonstrated anti-inflammatory activity with antipruritic action vs vehicle and was well tolerated in patients with AD5

Study Design and Patients

Results

Conclusions